Lung Cancer Screening Market Scope And Analysis

  • Report Code : TIPRE00029996
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 188
Buy Now

Lung Cancer Screening Market Scope and Analysis by 2030

Buy Now


Lung Cancer Screening Market Report Scope

Report Attribute Details
Market size in 2022 US$ 2.33 Billion
Market Size by 2030 US$ 4.36 Billion
Global CAGR (2022 - 2030) 8.2%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Cancer Type
  • Non-Small Cell Lung Cancer
By Technology
  • Low-Dose Computed Tomography
  • Chest X-Ray
  • Liquid Biopsy
By Age Group
  • 50 & Older and Below 50
By End User
  • Hospitals
  • Diagnostic Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Intelerad Medical Systems Incorporated
  • Nuance Communications Inc
  • GE HealthCare Technologies Inc
  • Medtronic Plc
  • Canon Medical Systems Corp
  • Koninklijke Philips NV
  • Siemens AG
  • CVS Health
  • bioAffinity Technologies Inc
  • Lung Cancer Screening Market - Recent Developments: 

    Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the lung cancer screening market. A few recent key market developments are listed below:

    • In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system.
    • In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software provider for enhancing breast imaging and lung screening productivity. The acquisition has expanded Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient health outcomes.
    • In May 2021, Genetron Holdings Limited partnered with Siemens Healthineers at the China Medical Equipment Fair. This partnership promoted the large-scale application of Genetron’s S5 platform and lung cancer 8-gene IVD assay in Chinese hospitals and provided NSCLC patients with efficient and accurate personalized diagnosis and treatment guidance.